DC 9703
Alternative Names: DC9703Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Obio Pharmaceutical Holdings
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA
- 18 Feb 2009 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)